New 'Living Drug' trial offers hope for Tough-to-Treat blood cancer
NCT ID NCT07185490
Summary
This early-stage study is testing a new type of treatment called IASO104, a CAR-T cell therapy, for people with multiple myeloma that has come back or stopped responding to other treatments. Doctors will give patients their own modified immune cells to try to fight the cancer. The main goals are to find a safe dose and see how well the body handles the treatment, while also getting an early look at whether it helps control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.